Healthcare Sector in India Monthly Update April 2013

7/30/2019 Healthcare Sector in India Monthly Update April 2013

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 1/15

Healthcare Sector in India

Monthly Update

April 2013



Healthcare – Monthly Update

Top Story

NRA

accredited

for

meeting

WHO

standards

Indian vaccine industry has reached an all time high with the World Health Organization

(WHO) declaring India's vaccine regulatory system meeting international standards. The

comprehensive review was conducted by an expert WHO team from 8 countries in Dec 2012.

The National Regulatory Authority of India (NRA) and its affiliated institutions have been

adjudged for fulfillment of WHO efficacy indicators for a functional vaccine regulatory

system.

The latest accreditation will pave the way for easy export of vaccines produced in the

country since the conformity to WHO standards guarantees Indian vaccine production lines

to be efficacious and safe and easily trusted.

News Update

General

Glivec faces patent plea dismissal

The Supreme Court declined Novartis AG's petition for patent protection of its cancer drug

Glivec although it has been patented in nearly 40 countries including the United States,

Russia and China. The Supreme Court dismissed the plea on the grounds of exorbitant price

and it not being a new medicine but an amended version of a known compound.

The legal blow has affected major pharma MNCs who target Indian market for driving sales.

The ruling has on the other hand been a boost for healthcare activists who have been

constantly demanding from the government to make medicines cheaper since patented

drugs constitute below 10% of total drug sales in India.

MSD Pharma files patent infringement litigation against Glenmark The USA based pharmaceutical company MSD Pharma has moved to the Delhi High Court to

bar Mumbai‐based Glenmark from selling generic versions of its anti diabetic drugs.

Glenmark Pharma launched generic versions of MSD Pharma’s anti diabetic drugs Januvia

and Janumet, under the names Zita and Zita Met last week. The generic version is beingmarketed at 20% rebated price to that of the innovator’s version that costs approximately

INR 40 per tablet.

Januvia and Janumet are patent protected for 20 years that was launched in 2008. Indian

jurisdiction of allowing launch of cheaper generic versions of existing patent protected drugs

is resulting in stiff competition between innovators and generic drug manufacturers.




Shasun Pharmaceuticals pacts with Debiopharm S.A.

Chennai based Shasun Pharmaceuticals has entered a licensing agreement with Switzerland‐

based Debiopharm S.A. for manufacture and promotion of Huperzine‐A. The drug is a

treatment of Alzheimer's disease. As per the agreement Shasun would be able to use theDebiopharm technology for manufacturing synthetic Huperzine‐A.

Huperzine‐A is proven to be a potent and reversible acetylcholinesterase inhibitor which can

remarkably improve memory deficit and cognitive performance in patients with Alzheimer's

disease.

News Update

Regulatory

Panel formed to plug irregularities in drug marketing A 4‐member committee has been formed to look into reviewing of practices and procedures

adopted by the drug controller and fix responsibilities. The committee will be led by former

Director of Institute of Medical Sciences, Banaras Hindu University, Varanasi, and T.M

Mahapatra along with former scientist Satyawan Singh of Central Drug Research Institute,

Lucknow, former Kerala Drug Controller Venkat Krishnan and a representative of the Chief

Vigilance Officer of Union Ministry of Health and Family Welfare as its members.

The panel will keep an eye on the Central Drugs Standard Control Organisation (CDSCO)

strict adherence to scientific requirements and regulatory compliance in granting marketingapproval and clinical trials on new drugs including fixed dose combinations. The committee

is also seeking the active involvement of Drug Controller General of India (DCGI) to enquire

into unlawful drug practices in the country, thereby helping in controlling illegal approval of

drugs in India.

KMSCL sells life saving drugs at subsidized rate

The Kerala government has initiated a remarkable strategy of controlling price of life saving

drugs. A government‐owned enterprise The Kerala Medical Services Corporation Ltd.

(KMSCL) is offering drugs at a substantially low price, even to the extent of one sixth the

price at which such drugs are available in retail stores.

KMSCL has taken upon this initiative by procuring medicines in bulk at a heavily discounted

price from drug manufacturers directly. The medicines thus procured are sold through a

chain of stores called Karunya that are located at five medical colleges in the state.

70 additional hospitals to get empanelled

The Indian Health Ministry is in the process of expanding healthcare service options in the

NCR for the central government employees. The Health Ministry is currently reviewing the




list of private hospitals, dental clinics and diagnostic facilities empanelled with the

government that would facilitate addition of at least 70 more private hospitals, eye care

centers and diagnostic facilities.

Around 10 new super and multispecialty hospitals, 10 mid segment general purpose

hospitals, 33 eye care centers, 10 dental clinics and 10 laboratories are in the process of

being empanelled. BL Kapoor Super Specialty Hospital, Max Hospitals at Patparganj and

Shalimar Bagh, Batra Hospital near Okhla, Rockland Hospital in South Delhi and Saroj

Hospital in Rohini are some of the hospitals to be included in the list of empanelled hospitals

among others. This would raise the total number of empanelled hospitals from current 130

to 200.

Pharmexcil to set up pharma storage warehouses abroad

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is in plans to set up

warehouse facilities in Latin America, Africa and Europe under the 'Brand India Pharma'campaign. The initiative is in view to encourage export business of small and medium Indian

pharma companies.

The warehouses will help the small and medium exporting pharma companies to stock their

products in desired conditions and supply as according to requirement. The Nigerian facility

is expected to be ready by Jun 2013. Pharmexcil has also announced that the 1st overseas

warehouse will give 75%, 50% and 33% subsidies for 3 years, respectively, to the user‐

companies.

Rajasthan Government drives Indian healthcare industry by free distribution of

Imatinib

Rajasthan Medical Services Corporation (RMSC) will be distributing generic version of

Novartis AG's Glivec (Imatinib) tablet for free from special counters at government hospitals.

This comes as part of Rajasthan Governments’ free medicine distribution scheme that was

launched in Oct 2010.

The blood cancer (chronic myeloid leukemia) medication, Glivec is currently sold at INR

0.12mn for a pack of 30 tablets. Blood cancer patients have to take one tablet daily, and in

order to bring relief to such patients, the state health department has decided to distribute

generic Imatinib tablets for free. The government is making an addition of 14 new anti‐

cancer drugs to be distributed free of cost totaling the cancer drugs provided for free to 39.

The pharma companies, who have shown interest in the project include Cipla, Glenmark,Naprod Life Sciences, United Biotech India and West Coast Pharmaceuticals.

Indian pharmaceutical sector soon to realize drug pricing policy

In a move to bring generic medicines under price control, the government has issued letters

to 4,000 Indian pharmaceutical industry manufacturers across the country to submit

relevant data. However, till now it has received responses from around 400 drug




manufacturers from the states of Maharashtra, Himachal Pradesh, Rajasthan, Gujarat and

Andhra Pradesh.

In accordance to the new pricing policy, the National Pharmaceutical Pricing Authority(NPPA) has asked pharmaceutical companies to submit complete data related to essential

medicines in order to fix their prices. The NPAA has also gone further by asking pharma

associations to ask their respective members to submit relevant data so that the 348

"essential" drugs pricing under National List of Essential Medicines (NLEM) could completed

in time.

News Update

Expansion

Plans

Dr Reddy’s launches Reclast generic version

Hyderabad based Dr Reddy’s Laboratories Ltd. has recently launched osteoporosis treating

zoledronic acid injection in the US market. The drug is a generic version of Swiss

pharmaceutical company Novartis AG’s Reclast (zoledronic acid) injection which is a

treatment for women suffering from osteoporosis post menopause. The injection is being

made available in a single use vial for intravenous infusion.

USFDA approval for the generic version will make the injection available at a price less than

at what Reclast is currently available now in the US bringing relief to its patients.

Elder penetrates cosmetics segment Mumbai based Elder Pharmaceuticals has plans of penetrating the Indian cosmetics segment.

The company will be investing INR 150 mn to INR 200 mn within the next 2‐3 years for

manufacturing and marketing of their products. The launch of new product line comes after

the company’s 40%‐60% partnership with Japan's Kose Corporation, which has been named

Kose Elder (India) Pvt. Ltd. for an interim period and will be involved in manufacturing and

selling Made in India cosmetics.

The companies will be focusing on skincare and body‐care products which will be essentially

available as OTC and cater to both mass as well as prestige segments.

Ranbaxy partners with Daiichi Sankyo to expand pharmaceutical business in Latin

America Gurgaon based Ranbaxy Laboratories are looking towards expanding its business in Latin

America by collaborating with its Japanese parent Daiichi Sankyo in pharmaceutical market.

Ranbaxy will be supporting its parent company’s Brazilian subsidiary, Daiichi Sankyo Brasil

Farmaceutica Ltda to penetrate the branded pharmaceutical generics market along with

establishing business of providing innovative products.




The business agreement will aid the Daiichi Sankyo Group to expand its presence in Brazil

through hybrid business model. Both Daiichi Sankyo and Ranbaxy are having considerable

pharmaceuticals business through innovative pharmaceuticals and generic products that are

being marketed by Daiichi Sankyo Brazil and Ranbaxy Farmaceutica respectively in Brazil.

Industry Expert Speak

Glivec faces patent plea dismissal – Ameet Hariani, Managing Partner - Hariani & Co.

Law Firm

“Henceforth, multinational pharma companies are likely to want that their patents are first

recognised in India before launch of a patented product.”

MSD Pharma

files

patent

infringement

litigation

against

Glenmark

– Ali

Asghar

Dholkawala, advocate and IP expert - Wadia Ghandy and Co. Law Frm

“Any data submitted to the government is not considered patent infringement under the

patent act. Also, grant of marketing approval doesn't amount to patent infringement under

the Drugs and Cosmetics Act of India.”

Pharmexcil to set up pharma storage warehouses abroad – Bhavin Mehta, Member –

Pharmexcil

"We have invited a large number of drug regulators from overseas market, which will

immensely help local pharma companies to promote the quality and affordability aspect as

envisaged in 'Brand India Pharma' campaign. The campaign has been initiated by Ministry of

Commerce and executed by Pharmexcil.

Transactions (Feb 2013 – Apr 2013)

Date Buyer Target Deal Size

(INR mn) % stake Deal Status

Type of

Transaction

25th Apr2013

InternationalFinance

Corporation

FortisHealthcare Ltd.

542 6 Planned Private Equity




23rd Apr2013

Somerset

Indus Capital

Partners

Cygnus

Medicare Pvt.

Ltd.

N.A. N.A. Completed Private Equity

16th Apr2013

FulcrumVenture India

ShieldHealthcare Pvt.

Ltd.218.2 N.A. Completed Private Equity

15th Apr

2013

Seedfund

&

AsianHealthcare

Fund

Total Dental

Care Pvt. Ltd. 500 N.A. Completed Private Equity

12th Apr2013

Singaporebased investor

Amrish

OncologyServices Pvt.

Ltd.

330 N.A. Completed Private Equity

12th Apr2013

OrbiMedAdvisors

ClarisLifesciencesLtd.

2013.04 N.A. Completed Private Equity

2nd Apr2013

India VentureAdvisors

Global BarodaHospital

N.A. N.A. Completed Private Equity

1st Apr2013

MortaraInstruments

IncCardiac Science 1140 N.A. Planned M&A




25th Mar2013

ChrysCapital

Ipca

Laboratories

Ltd.

2174 4 Completed Private Equity

22nd Mar2013

Jacob BallasCapital India

Pvt. Ltd.

Vivimed LabsLtd.

670 13.1 Completed Private Equity

22nd Mar

2013

Quadria

Capital

Milestone

Religare

Investment Advisors Pvt.

Ltd.

N.A. 100 Completed Private Equity

20th Mar2013

Intel andSequoiaCapital

Healthkart 760 N.A. Completed Private Equity

15th Mar2013

Fresenius KabiIndia Pvt. Ltd.

ParenteralDrugs IndiaLtd.

2000 N.A. Completed M&A

13th Mar2013

Route One Strides Arcolab 558.1 N.A. Completed Private Equity

11th Mar2013

Temasek Holdings

HealthcareGlobal

Enterprises

(HCG)





2nd Mar2013

IFC Hikal Ltd. 435 N.A. Planned Private Equity

28th Feb2013

Cipla Ltd.Cipla MedproSouth Africa

Ltd.391.32 N.A. Completed M&A

28th Feb

2013 Mylan Inc.

Agila

Specialties Pvt.Ltd.

86,000 100 Completed M&A

25th Feb2013

WestBridge

CapitalPartners

&

TA Associates

Dr. LalPathLabs

2,434 N.A. Completed Private Equity

25th Feb2013

LighthouseFunds

SurakshaDiagnostic Pvt.Ltd.


21st Feb2013

HelionVenturePartners

LifeCellInternational


19th Feb2013

IMCD GroupB.V

IndchemInternational

N.A. N.A. Completed M&A




14th Feb2013

Vivimed LabsFinoso Pharma

Pvt. Ltd.150 N.A. Completed M&A

8th Feb2013

Ma FoiStrategic

Consultants

Oviya MedSafePvt. Ltd.

N.A. 17.5 Completed M&A

Annual Financial Results – Revenue (INR mn)

Companies FY ‘09 FY ‘10 FY ‘11 FY ‘12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories

(DRL)69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKline ConsumerHealthcare Ltd.

19,757.6 23,693.3 27,688.6 28,857.3

Glenmark PharmaceuticalsLtd.

21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0




Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy Laboratories Ltd. 75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun PharmaceuticalsIndustries Ltd.

42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals Ltd. 16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

* Change in Financial Year Ending

Annual Financial Results – Income (INR mn)

Companies

FY

‘09

FY

‘10

FY

‘11

FY

‘12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0


Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0


(DRL)‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline ConsumerHealthcare Ltd.

2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5




Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6

Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4

Sun Pharmaceuticals

Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5


Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1

* Change in Financial Year Ending

Quarterly Financial Results – Revenue (INR mn)

Companies Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Oct -Dec

2012

Biocon Ltd. 5,892.2 5,770.0 5,924.0 6,342.2

Blue Star Ltd. N.A. N.A. N.A. N.A.


Cipla Ltd. N.A N.A. N.A. N.A.

Dabur India Ltd. 13,858.3 14,620.0 15,372.2 16,307.2





(DRL)26,584.0 25,406.0 28,809.0 28,651.6

GlaxoSmithKline Consumer

Healthcare Ltd.

8,608.7 7,869.6 8,275.4 7,090.7


10,751.2 10,404.1 12,551.9 13,812.6

Jubilant life Sciences Ltd. 12,235.9 12,358.9 12,197.3 13,018.1

Lupin Ltd. 20,063.7 22,191.5 22,392.6 24,658.7

Nestle India Ltd. 20,558.7 19,865.8 21,155.9 21,526.4


Piramal Enterprises Ltd. 7,055.3 7,472.4 8,630.3 9,935.7

Ranbaxy Laboratories Ltd. 36,954.0 31,740.6 26,513.9 (68,096.4)

Siemens India Ltd. 37601.432 34,141.3 34,141.3 24,508.6

Strides Arcolab Ltd. 5,274.7 5,082.9 5,773.4 N.A.


23,299.3 26,581.4 26,638.6 28,520.1


Wockhardt Ltd. 12,413.90 14,258.2 13,474.4 14,350.4

Quarterly Financial Results – Income (INR mn)

Companies Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Oct -Dec

2012

Biocon Ltd. 978.0 790.0 896.5 917.6

Blue Star Ltd. N.A. N.A. N.A. N.A.

Cadila Healthcare Ltd. 1,708.8 1,947.9 951.4 1,029.1




Cipla Ltd. N.A. N.A. N.A. N.A.

Dabur India Ltd. 1,705.1 1,494.0 2,023.7 2,111.1

Dr. Reddy’s Laboratories(DRL)

3,427.0 3,360.0 3,925.0 3,633.1

GlaxoSmithKline Consumer

Healthcare Ltd.1,319.7 1,066.0 1,285.5 696.5


1,482.7 782.8 1,567.5 2,129.2

Jubilant life Sciences Ltd. ‐635.3 50.1 1,520.0 266.9

Lupin Ltd. 1,556.4 2,803.9 2,904.6 3,352.3

Nestle India 2,757.3 2,459.7 2,673.1 2,789.3


Piramal Enterprises Ltd. (386.8) 40.8 (920.2) 610.7

Ranbaxy Laboratories Ltd. 12,467.6 ‐5,857.3 7,541.7 (19,076.6)

Siemens India Ltd. 3,040.0 (157.6) (157.6) 730.7

Strides Arcolab Ltd. 6,420.7 904.8 524.9 N.A.


8202.1 7,955.5 3,196.4 8,813.0

Torrent Pharmaceuticals Ltd. ‐16.5 1,018.5 1,072.5 1,123.3

Wockhardt Ltd. ‐1,916.4 3,779.7 4,535.5 4,278.4




Research on India (ROI) is a leading source for market research on various sectors in India

that offers premium research content from worldwide publishers of market research

reports.

Contact us:

W: www.researchonindia.com

T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5

E: [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.

Events Calendar

Hands-on

Workshop

on

Molecular

Biotechnology and Bioinformatics Date: 6th to 10th May 2013

Venue: International Center for Stem Cells,Cancer and Biotechnology (ICSCCB), Pune

City: Pune, MaharashtraContact Person: Prof. Dr. Sheo Mohan SinghOrganizer: ICSCCB

Contact No: +91 9545089202E‐Mail: [email protected]

Website: icsccb.org/workshops

Drug Delivery

&

Complex

Generics

Date: 28th to 30th May 2013Venue: Holiday Inn International, Sakinaka

JunctionCity: Mumbai, MaharashtraContact Person: Pallavi Mhapankar

Organizer: UBM IndiaContact No: +91 22 61727001/+91 22 61727272

Website: atnd.it/11koVgA

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

https://www.facebook.com/researchonindia

Healthcare Sector in India Monthly Update April 2013

Documents

Transcript of Healthcare Sector in India Monthly Update April 2013